Senior Business Developer,
Dr. Claes Post is a senior business development person at Linköping University. He is also consultant to the Swedish VC organisation ALMI Invest for life science investments.
Previously Claes Post, M. Pharm, Ph.D. has a long-standing career in the Life Science Industry, VP preclinical research at Astra (pain and inflammation), VP preclinical and clinical CNS research and development at Pharmacia, Milan, Italy and head of clinical CNS reseach and development at Pharmacia & Upjohn, Sweden. During the last 10 years, Dr. Post has mainly been engaged in the start-up of VC-financed companies based on excellent research from Swedish universities. For the last 2,5 years has has been General Manager of Karolinska Institutet Innovations AB, Currently Dr. Post is engaged in Linköping university based deal-sourcing and development of projects and from the medical faculty.
Dr. Post has been professor (adjunct) in neuropharmacology at Uppsala university, Lund university and the Karolinska Institute. Dr. Post´s research has mainly concerned pain and neurodegeneration, with more than 120 peer-reviewed articles. The research has been performed in the cross-roads between basic neuropharmacology, clinical research and applied industry based research.
Dr. Post is member of the Swedish Academy of Pharmaceutical Sciences and the Royal Society of Sciences.
- Technology Transfer in the Swedish context ( 513Kb)
Sweden has a strong tradition of excellent academic research with a number of innovations based on succesful transfer from academia to companies like Astra, Pharmacia, and others. The focus of my contribution will discuss some of these ground breaking technolgy transfers and how tomorrow´s innovations will be supported from the combined university based Technology transfer organisations, venture capital, corporations, entrepreneurs. The Swedish system is operating within the"Teacher´s Excempt" system whereby university employees own their inventions. The primary focus of the talk will be life science.